Compare Equinor ASA (EQNR) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Smith & Nephew plc — how do they compare? Equinor ASA trades at $35.61 (market cap $82.75B), while Smith & Nephew plc trades at $31.2 (market cap $12.81B). The key difference: Equinor ASA is far larger — about 6.5× Smith & Nephew plc's market cap, and Equinor ASA pays the higher dividend (4.24%). Which is the better fit depends on your goals.
| EQNR | SNN | |
|---|---|---|
Market Cap | $82.75B | $12.81B |
Sector | Energy | Health |
52-Week High | $42.40 | $38.70 |
52-Week Low | $22.41 | $28.73 |
Enterprise Value | $94.51B | $15.58B |
Dividend Yield | 4.24% | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $36.19, up 0.36% on the day, with a bullish technical signal from moving averages. Recent earnings show mixed results, with a Q1 2026 beat but a Q3 2025 miss. The company maintains a strong balance sheet with $21.24B in cash and a low EV/EBITDA of 2.39. Recent news highlights strategic investments in subsea projects and a share buy-back program, reinforcing growth commitments.
The outlook is cautiously optimistic, supported by low valuation metrics and strategic asset expansions. Key risks include volatile energy prices and declining net income margins. Analyst sentiment is mixed, with a 30.43% buy rating, suggesting potential upside but requiring monitoring of execution on production targets.
Smith & Nephew (SNN) trades at $29.83, down 4.02% today, with a bearish technical signal. The company reported revenue of $5.81 billion in 2024, with net income of $412 million, showing improved profitability. Recent news highlights product launches in robotics and wound care, supported by a $500 million share buyback. Analyst consensus is mixed, with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility.
Outlook is balanced: strong free cash flow and innovation in medical technology offer growth potential, but near-term risks include competitive pressures and debt levels. The stock's valuation at a P/E of 21.51 is reasonable if earnings growth sustains, yet technical weakness suggests caution. Investors should weigh solid fundamentals against market sentiment and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
